Article

Efectividad del misoprostol para el aborto en el primer trimestre del embarazo en adolescentes.

MediSur 01/2008;
Source: DOAJ

ABSTRACT Fundamento: La prostaglandina sintética PGE1 conocido como misoprostol es un análogo de la prostaglandina E. En ginecología se utiliza para la maduración del cérvix uterino y provocar modificaciones que favorezcan la expulsión rápida del producto de la concepción en el primer trimestre del embarazo. Objetivo: Demostrar la efectividad del misoprostol para el aborto medicamentoso en el primer trimestre del embarazo en adolescentes. Métodos: Estudio descriptivo, prospectivo, de serie de casos que incluyó 763 adolescentes de la provincia de Cienfuegos que desde agosto del 2005 hasta junio del 2007 solicitaron, la interrupción de la gestación por aborto medicamentoso empleando el misoprostol. Para la ejecución de este método se utilizó la guía de instrumentación metodológica creada por el Ministerio de Salud Pública para el uso del misoprostol por vía vaginal en la inducción del aborto. Se tuvo en cuenta el consentimiento de las pacientes y sus padres. Resultados: La expulsión se produjo en el 93,4 % de las adolescentes, de ellas el 66 % tenía 8 semanas de gestación, 89 % eran nulíparas y 2,6 multíparas. Los síntomas más frecuentemente producidos por el método fueron: sangrado (42 %), dolor (38,4 %). Conclusiones: El empleo del misoprostol fue efectivo para la interrupción del embarazo en el primer trimestre en adolescentes.

Palabras clave: Misoprostol; Agentes abortivos no esteroides; Aborto terapéutico; Aborto inducido

ABSTRACT

Title: Effectiveness of the misoprostol for the abortion in the first trimester of the pregnancy in adolescents.

Background: Synthetic prostaglandin PGE1 known ad misoprostol is an analog of the E prostaglandin. In the gynecological field it is used for the cervix uterine maturation and in this way it provokes modifications which favor the fast expel of the product of conception in the first trimester of pregnancy. Objectives: to show the effectiveness of misoprostol for medicamentous abortion in the first trimester of adolescents´ pregnancy. Methods: a descriptive, series cases, prospective study which included 763 adolescents in Cienfuegos province from August 2005 to June 2007. Adolescents with their parents' consent asked the doctors for the interruption of their pregnancy status using misoprostol as medicamentous abortion. For the performance of this method, a methodological instrumentation guide created by the Public Health Minister for the usage of misoprostol in vaginal pathway for the abortion induction was used. Results: The expelling of the fetus was successful in 93, 4 % of the adolescents, 66% of them were in their 8 weeks of gestation, 89 % were nulliparae, and 2, 6 were multiparae. The most frequent symptoms produced for this method were bleeding (42%), and pain (38, 4%). Conclusions: the usage of misoprostol was effective for the interruption of pregnancy in the first trimester in adolescents.

Key words: MISOPROSTOL; ABORTIFACIENT AGENTS; ABORTION, THERAPEUTIC; ABORTION, INDUCED

0 Bookmarks
 · 
353 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the induction-to-abortion time of 3 pharmacokinetic-based protocols at 13-20 weeks of gestation. A randomized trial was conducted on 153 patients. The oral group (n = 51) received 100 microg misoprostol orally every 2 hours, the vaginal group (n = 51) received 200 microg misoprostol vaginally every 4 hours, and the sublingual group (n = 51) received 100 microg misoprostol sublingually every 2 hours. The mean induction-to-delivery time was shorter in the sublingual group (mean, 651 +/- 507) as compared to the vaginal group (mean, 1,056 +/- 634, p = 0.01). The number of patients who delivered within 12 hours was significantly higher in the sublingual group (n = 39, 78%) as compared to the oral (n = 26, 52%) and vaginal (n = 20, 40%) groups (p < 0.001). The numbers of patients who delivered within 24 hours were comparable in the sublingual (n = 47, 94%) and oral (n = 46, 92%) groups but higher than in the vaginal group (n = 39, 78%; p = 0.02). The total misoprostol dose was 543 +/- 422 microg in the sublingual group, 878 +/- 533 microg in the vaginal group and 741 +/- 413 microg in the oral group (p < 0.001). A pharmacokinetic-based application of 100 microg of sublingual misoprostol every 4 hours is more effective for induction of second-trimester abortion as compared to 100 microg oral misoprostol every 2 hours and 200 microg vaginal misoprostol every 4 hours.
    The Journal of reproductive medicine 03/2005; 50(3):173-80. · 0.75 Impact Factor
  • Obstetrics and Gynecology 09/2002; 100(2):383. · 4.80 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: During pregnancy, uterine contractility is suppressed by progesterone. The progesterone receptor inhibitor, mifepristone, increases uterine contractility and sensitizes the myometrium to prostaglandin. The maximum effect is achieved when prostaglandins are administered 36 to 48 h after mifepristone. The recommended prostaglandin analogue used with mifepristone for medical abortion is misoprostol. It is licensed for oral use but other routes are used to improve efficacy. The difference in the effect of various routes of administration can be explained by pharmacokinetics and the effect on uterine contractility. Oral misoprostol leads to an increased uterine tonus without regular contractions. In contrast, vaginal and sublingual administration leads to a longer-lasting effect on the myometrium and subsequent development of regular contractions. Recently, a new oral slow-release preparation of misoprostol has been studied. Future studies will show whether prostaglandin analogues with a prolonged effect on the myometrium may further improve the regimens for medical abortion.
    Contraception 08/2006; 74(1):31-5. · 3.09 Impact Factor

Full-text

Download
3 Downloads
Available from